Market Cap | 75.01M | P/E | - | EPS this Y | 18.60% | Ern Qtrly Grth | - |
Income | -24.99M | Forward P/E | -3.17 | EPS next Y | 3.50% | 50D Avg Chg | 3.00% |
Sales | 2.84M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 11.00% |
Dividend | N/A | Price/Book | 2.30 | EPS next 5Y | - | 52W High Chg | -25.00% |
Recommedations | 2.00 | Quick Ratio | 0.59 | Shares Outstanding | 37.82M | 52W Low Chg | 94.00% |
Insider Own | 51.93% | ROA | -42.68% | Shares Float | 17.84M | Beta | 0.98 |
Inst Own | 2.82% | ROE | -98.23% | Shares Shorted/Prior | 15.87K/23.96K | Price | 2.09 |
Gross Margin | -165.02% | Profit Margin | - | Avg. Volume | 19,456 | Target Price | 6.00 |
Oper. Margin | -813.31% | Earnings Date | - | Volume | 5,044 | Change | 2.45% |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
EF Hutton | Buy | Apr 19, 23 |
EF Hutton | Buy | Mar 30, 23 |
EF Hutton | Buy | Mar 23, 23 |
JonesTrading | Buy | Nov 8, 22 |
Maxim Group | Buy | Mar 24, 22 |
EF Hutton | Buy | Nov 19, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Rhode Peter | See Remarks See Remarks | Dec 11 | Option | 0.14 | 14,000 | 1,960 | 77,500 | 12/11/23 |
Flowers Lee | SVP of Business Deve.. SVP of Business Development | Dec 08 | Option | 0.14 | 7,501 | 1,050 | 118,809 | 12/11/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Oct 19 | Option | 0.14 | 47,249 | 6,615 | 621,195 | 10/23/23 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Sep 14 | Buy | 2.0782 | 1,800 | 3,741 | 15,314,868 | 09/18/23 |
Winer Gary M | Director Director | Sep 13 | Buy | 2.05 | 1,587 | 3,253 | 17,000 | 09/15/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 13 | Buy | 2.098 | 5,000 | 10,490 | 573,946 | 09/15/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 11 | Buy | 2.07 | 10,000 | 20,700 | 568,946 | 09/13/23 |
Winer Gary M | Director Director | Sep 08 | Buy | 2 | 600 | 1,200 | 15,413 | 09/12/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 07 | Buy | 1.99 | 10,000 | 19,900 | 558,946 | 09/08/23 |
Winer Gary M | Director Director | Sep 05 | Buy | 1.85 | 463 | 857 | 14,813 | 09/07/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 06 | Buy | 1.9498 | 5,000 | 9,749 | 548,946 | 09/07/23 |
Flowers Lee | SVP of Business Deve.. SVP of Business Development | Jun 08 | Buy | 2.16 | 10,000 | 21,600 | 111,308 | 06/09/23 |
Flowers Lee | SVP of Business Deve.. SVP of Business Development | Jun 08 | Option | 0.14 | 5,356 | 750 | 101,308 | 06/09/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Jun 09 | Buy | 2.0643 | 20,000 | 41,286 | 543,946 | 06/09/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Jun 07 | Buy | 2.12 | 24,696 | 52,356 | 523,946 | 06/08/23 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Jun 01 | Buy | 1.58 | 1,600 | 2,528 | 15,313,068 | 06/02/23 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | May 30 | Buy | 1.55 | 5,000 | 7,750 | 15,311,468 | 06/01/23 |
Winer Gary M | Director Director | May 30 | Buy | 1.51 | 1,350 | 2,038 | 14,350 | 06/01/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | May 25 | Buy | 1.64 | 40,000 | 65,600 | 460,188 | 05/31/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | May 22 | Buy | 1.57 | 58,486 | 91,823 | 420,188 | 05/24/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 12 | Buy | 2.61 | 30,000 | 78,300 | 312,952 | 09/14/22 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Sep 02 | Buy | 2.57 | 10,000 | 25,700 | 15,296,468 | 09/07/22 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Aug 26 | Buy | 2.55 | 20,000 | 51,000 | 265,752 | 08/30/22 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Aug 24 | Buy | 2.55 | 90,300 | 230,265 | 245,752 | 08/26/22 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Jun 13 | Buy | 2.27 | 66,452 | 150,846 | 155,452 | 06/15/22 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Jun 10 | Buy | 2.188 | 1,520 | 3,326 | 15,286,468 | 06/13/22 |
Winer Gary M | Director Director | Jun 08 | Buy | 2.2 | 3,500 | 7,700 | 13,000 | 06/10/22 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Jun 07 | Buy | 2.28 | 3,000 | 6,840 | 15,284,948 | 06/09/22 |
Greene Rick S. | Director Director | Jun 02 | Buy | 2.0918 | 4,800 | 10,041 | 8,411 | 06/06/22 |
Rhode Peter | See Remarks See Remarks | Jan 14 | Option | 0.18 | 1,715 | 309 | 48,500 | 01/19/22 |